Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022

LONDON, July 4, 2018 /PRNewswire/ -- Report Scope:
This research report categorizes the drugs for urinary incontinence and overactive bladder by type. Product type include Idiopathic Bladder Overactivity, and Neurogenic Bladder Overactivity.

Download the full report: https://www.reportbuyer.com/product/5370230

Report Includes:
- 96 data tables.
- An overview of the global market for drugs for urinary incontinence and overactive bladder
- Analyses of global market trends, with data from 2013 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Coverage of types of urinary incontinence such as urge incontinence (UUI), stress incontinence (SUI), overflow incontinence (OUI), functional incontinence (FUI), and mixed symptoms (MUI)
- Identification of effective treatment options for incontinence and overactive bladder
- Analyses of Idiopathic bladder overactivity and neurogenic bladder overactivity and their probable causes
- Detailed profiles of key competitors of the market, including Astellas Pharma Inc., Pfizer, Inc., Allergan, PLC., Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals A/S

Summary
Global urinary incontinence and overactive bladder market growth outlook is positive. with significant growth potential This disease is widely prevalent among the elderly and women population globally. At the same time, emerging markets growth, sedentary lifestyles, health insurance reforms, rising ageing population, technological advances aiding research and development activities, diagnosis and treatment is driving the demand of drugs for urinary incontinence and overactive bladder market.

The market for urinary incontinence and overactive bladder drugs is expected to be driven by advances in drug development. Mainly, site specific local drug delivery, lower side effects, different forms of medications and combination therapy are the major trends in the market.

The drugs for urinary incontinence and overactive bladder market reached a value of nearly REDACTED in 2017 and is expected to grow at a compound annual growth rate (CAGR) of REDACTED to nearly REDACTED by 2020.

The drugs for urinary incontinence and overactive bladder market is dominated by one large player, constituting for REDACTED.Major players in the market are Astellas, Pfizer, Allergan, Merck and others.

Idiopathic bladder overactivity accounted for the largest share of the drugs for urinary incontinence and overactive bladder market in 2017 at REDACTED. The highest growth is projected to also expected to come from the same segment, which is forecasted to grow at a CAGR of REDACTED.

Asia Pacific is the largest drugs for urinary incontinence and overactive bladder market, accounting for REDACTED of the global market.It was followed by North America and Western Europe region.

Going forward, Asia Pacific is expected to witness the fastest growth in the drugs for urinary incontinence and overactive bladder market, estimated at grow at a CAGR of REDACTED, followed by Africa, which is expected to grow at a CAGR of REDACTED.

The USA is the largest market in terms of value and in the drugs for urinary incontinence and overactive bladder market. China and India are forecasted to have the fastest growth, growing at a CAGR of REDACTED and REDACTED, respectively.

The market is challenged by restraints such as decline in patent expiration of drugs, increasing popularity of alternative treatments and therapies, social stigmas associated with the disease and lack of awareness among people in many countries globally.

Download the full report: https://www.reportbuyer.com/product/5370230

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/drugs-for-urinary-incontinence-and-overactive-bladder-global-markets-to-2022-300676364.html

SOURCE ReportBuyer